PKC lambda/iota CRISPR/Cas9 KO Plasmid (m): sc-422263

Overview

Prkci encodes the atypical protein kinase C isoform PKC lambda/iota, a serine/threonine kinase that functions downstream of polarity complexes such as PAR3–PAR6 and contributes to establishment of apical–basal polarity, tight junction organization, and asymmetric cell division. PKC lambda/iota integrates cues from PI3K- and small GTPase-regulated signaling to coordinate cytoskeletal remodeling, vesicle trafficking, and epithelial morphogenesis. In mouse models, altered Prkci activity has been linked to disrupted tissue architecture and aberrant developmental and immune cell programs, making it relevant to studies of epithelial integrity, differentiation, and stress-responsive signaling. Its central role in polarity and growth control pathways also connects Prkci dysregulation to mechanisms that are frequently interrogated in cancer biology and metabolic research contexts.

PKC lambda/iota CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Prkci gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Prkci together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Prkci open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PKC lambda/iota protein expression.

This CRISPR knockout system enables efficient generation of Prkci-deficient cell models for investigation of PKC lambda/iota signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Prkci exon(s) critical for PKC lambda/iota function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Prkci genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by PKC lambda/iota CRISPR/Cas9 KO Plasmid (m) and PKC lambda/iota CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Prkci locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by PKC lambda/iota HDR Plasmid (m) and PKC lambda/iota HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Prkci homology arms to support homology-directed repair at defined Prkci target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.